Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-AnalysisPsyArXiv · 2026-07-17The ANCHOR Framework for Psychedelic AccompanimentPsyArXiv · 2026-07-15Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-095-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1protocols.io · 2026-06-21Altered States, Enhanced Potential: Psychedelics and Physical PerformancePsyArXiv · 2026-06-12Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depressionPsyArXiv · 2026-06-10Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.Molecular psychiatry · 2026-05-29Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic ReviewPsyArXiv · 2026-05-24Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.PsyArXiv · 2026-05-1426-CCC-15854-ACC TALK ABOUT A BAD TRIP!: PSILOCYBIN USE WITH PRE-EXISTING CARDIOVASCULAR DISEASE, A CASE REPORTJACC · 2026-04-01Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”PsyArXiv · 2026-03-30Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled TrialPsyArXiv · 2026-03-26Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-03-20Explainable AI framework for psilocybin depression treatment optimizationFrontiers in Computer Science · 2026-03-16Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.BMJ open · 2026-03-12Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training ProgramsPsyArXiv · 2026-03-11Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific ComparisonsPsyArXiv · 2026-03-02Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert PerspectivesPsyArXiv · 2026-02-19Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials.Neuropharmacology · 2026-02-15Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCDPsyArXiv · 2026-02-11Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-RESTPsyArXiv · 2026-01-15Psilocybin for Treatment-Resistant OCD: A Randomized Controlled TrialPsyArXiv · 2026-01-15Marketing by online tobacco retailers: An observational cross-sectional study.Tobacco induced diseases · 2026-01-01Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic RetreatPsyArXiv · 2025-12-31Which Psychotherapy Model Should be Used in Psilocybin Treatment for Depression?Trends in psychiatry and psychotherapy · 2025-12-17The entropic brain todayPsyArXiv · 2025-12-12Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective studyPsyArXiv · 2025-12-10The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female MiceThe Journal of Neuroscience · 2025-12-10Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover TrialPsyArXiv · 2025-11-16An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109PDXScholar (Portland State University) · 2025-10-02Blunted psychedelic drug effects in older adultsPsyArXiv · 2025-09-04Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPsyArXiv · 2025-07-15Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2025-07-01Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use DisorderPsyArXiv · 2025-06-10Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approachPsyArXiv · 2025-06-06Age and cannabis co-use moderate experience and perceived benefits of psilocybinPsyArXiv · 2025-05-22Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatmentsPsyArXiv · 2025-05-16Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters.Scientific reports · 2025-04-22Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.BMJ open · 2025-04-15Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious communityPsyArXiv · 2025-03-27Psychedelics and autobiographical memory - Six open questionsPsyArXiv · 2025-03-11Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing StudyPsyArXiv · 2025-03-07Elucidating the Phase I metabolism of psilocin in vitroArchives of Toxicology · 2025-03-01Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online samplePsyArXiv · 2025-02-28Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing MushroomsPsyArXiv · 2025-02-28The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.PsyArXiv · 2025-02-25New frontiers in the biosynthesis of psychoactive specialized metabolites.Current opinion in plant biology · 2024-12-01Narrative review of psilocybin, an important psychoactive substance with potential peri-anesthetic implicationsTrends in Anaesthesia and Critical Care · 2024-11-30Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trialPsyArXiv · 2024-11-04Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin ExpertsPsyArXiv · 2024-10-31The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.PsyArXiv · 2024-10-18Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review ProtocolPsyArXiv · 2024-10-07Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.Brain sciences · 2024-08-18Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-usersPsyArXiv · 2024-07-28Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectanciesPsyArXiv · 2024-06-105-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case studyPsyArXiv · 2024-06-07Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMAPsyArXiv · 2024-06-07Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related PsychopathologyPsyArXiv · 2024-05-26Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapyPsyArXiv · 2024-05-17Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use DisordersResearch Posters · 2024-05-02Do undergraduates’ views of psychedelics relate to the context for psychedelic use?PsyArXiv · 2024-04-24Who will staff the psychedelic resurgence?Open Access Government · 2024-04-09Development of a digital intervention for psychedelic preparation (DIPP).Scientific reports · 2024-02-19Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical studyPsyArXiv · 2024-01-11Fire Kasina advanced meditation produces experiences comparable to psychedelic and near-death experiences: A pilot study.Explore (New York, N.Y.) · 2024-01-01Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and OverviewPsyArXiv · 2023-12-26Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. PsilocybinPsyArXiv · 2023-12-26Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approachPsyArXiv · 2023-11-22Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approachPsyArXiv · 2023-11-22A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issuesPsyArXiv · 2023-10-27Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin usePsyArXiv · 2023-10-14Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility studyPsyArXiv · 2023-10-11A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic aminesJournal of Biological Chemistry · 2023-09-09“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case reportPsyArXiv · 2023-08-16Leveraging psychedelic therapies for binge eating disorderOpen Access Government · 2023-07-10Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on PsilocybinPsyArXiv · 2023-07-06Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative studyPsyArXiv · 2023-06-30A regulatory framework review of Schedule I psychedelics in the United StatesJACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2023-06-12The treatment of abandonment anxiety with MDMA and LSDPsyArXiv · 2023-06-09Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal StudyPsyArXiv · 2023-06-09Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case studyPsyArXiv · 2023-06-09The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of ConsciousnessPsyArXiv · 2023-06-04Is Microdosing a Placebo?PsyArXiv · 2023-06-04Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disordersbioRxiv · 2023-05-18Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’PsyArXiv · 2023-04-28509. Meta-Analysis of Functional Neuroimaging Studies of the Effects of Serotonergic Psychedelics on Neural ActivityBiological Psychiatry · 2023-04-09Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCDPsyArXiv · 2023-03-17Understanding psychedelic 'mystical experience'-A case examplePsyArXiv · 2023-03-10Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case studyPsyArXiv · 2023-03-10Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case studyPsyArXiv · 2023-03-10The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging StudiesEuropean Psychiatry · 2023-02-28Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekstPsyArXiv · 2023-01-04Manuel de Yale pour la Thérapie de la Dépression Assistée par la PsilocybinePsyArXiv · 2022-11-15Serotonergic antidepressant use is associated with weaker psilocybin effectsPsyArXiv · 2022-10-28Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trialPsyArXiv · 2022-10-19Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355PsyArXiv · 2022-10-05Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.Neuropharmacology · 2022-08-15From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)PsyArXiv · 2022-07-07A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for DepressionPsyArXiv · 2022-07-01Neuroimaging in psychedelic drug development: Past, present, and futurePsyArXiv · 2022-06-30A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed MindsPsyArXiv · 2022-05-10Skepticism About Recent Evidence that Psilocybin Opens Depressed MindsPsyArXiv · 2022-04-28Therapeutic use of psilocybin: Practical considerations for dosing and administration.Frontiers in psychiatry · 2022-01-01Predictors of Psychedelic Experience: A Thematic AnalysisPsyArXiv · 2021-12-21A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive EffectsPsyArXiv · 2021-12-14Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability testPsyArXiv · 2021-11-23Psychedelics and Mindfulness: A Systematic Review and Meta-AnalysisPsyArXiv · 2021-10-11Naturalistic Entheogenics: Précis of Philosophy of PsychedelicsPsyArXiv · 2021-07-08Psilocybin for Depression: The ACE Model ManualPsyArXiv · 2021-07-05Psychedelic Assisted Therapy for Major Depressive Disorder: A ReviewPsyArXiv · 2021-06-27Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trialsPsyArXiv · 2021-06-14Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trialsPsyArXiv · 2021-06-14Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analysesPsyArXiv · 2021-06-10Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and WellbeingPsyArXiv · 2021-05-31Future Directions for Clinical Psilocybin Research: The Relaxed Symptom NetworkPsyArXiv · 2021-05-19New insights into the clinical and nonclinical effects of psychedelic substances: an integrative reviewPsyArXiv · 2021-05-05Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)PsyArXiv · 2021-04-02Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)PsyArXiv · 2021-03-24Blinding and Expectancy Confounds in Psychedelic Randomised Controlled TrialsPsyArXiv · 2021-03-08The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)PsyArXiv · 2020-08-13Confirmatory factor analysis of Mystical Experience in Freediving as a recreative way to higher efficiency in sport performance and planet saving and money makingPsyArXiv · 2020-08-07Global Drug SurveyPsyArXiv · 2020-04-12Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2020-01-01New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological IssuesCurrent Addiction Reports · 2019-04-22These fungi drug cicadas with psilocybin or amphetamine to make them mate nonstopAccess Science · 2019-01-01Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosersPsyArXiv · 2018-11-02Psychoactive plant- and mushroom-associated alkaloids from two behavior modifying cicada pathogensbioRxiv · 2018-07-24Homological scaffolds of brain functional networks.Journal of the Royal Society, Interface · 2014-12-06ChemInform Abstract: COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR SPECTROSCOPYChemischer Informationsdienst · 1981-07-14Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopyJournal of Medicinal Chemistry · 1981-02-01Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache.Experientia · 1974-12-15